Partner with us

Driving innovation through strategic collaborations

Since its incorporation, Quantoom Biosciences has built strong partnerships with key international academic institutions and strategic organizations in order to produce a truly freedom-to-operate Nfinity platform.

We welcome parties interested in working with Quantoom Biosciences to contact us at

Etherna logo_rgb

Our partnership with eTheRNA enables the transfer of materials and data necessary for the development of the Ntensify Maxi. Quantoom will be responsible for commercialization of the system worldwide with sales-related royalties payable to eTheRNA. International sales and distribution are expected to commence in 2023.


The Afrigen partnership paves the way for the development of the first-ever African-owned COVID-19 vaccine. Afrigen hosts the World Health Organization’s Global mRNA Vaccine Technology Transfer Hub and is working to facilitate the production of mRNA vaccines at over 15 designated manufacturing sites in LMICs across the world. The collaboration focuses on development of a novel mRNA vaccine using intellectual property from the collaboration partners, as well as developing new IP, to supercharge access to the vaccine.


Early 2023, Quantoom Biosciences entered into a public-private partnership with Immunewatch and the University of Antwerp. The goal of this project is to assess if a detailed analysis of the T-cell receptor response can be utilized to inform vaccine design and augment the vaccine development process. It is believed that the proposed methodology could reduce time and expenditures in the preclinical development process of vaccines. As a proof-of-concept, the team has chosen to work on a rabies vaccine candidate.

The collaborative investment by Biotechnology and Biological Sciences Research Council (BBSRC), the Foreign, Commonwealth and Development Office (FCDO) and the Bill & Melinda Gates Foundation, totalling almost £40m, promotes a ‘one health’ approach towards improving the health and wellbeing of animals and humans on a global scale. The new Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) will bridge the gaps between research and expertise in process development and manufacturing.

Read the press release


The NucNanoFish project, led by ICRAD, has assembled a consortium of six partners, with highly complementary expertise to develop new vaccines to prevent fish viral diseases for sustainable aquaculture.

The consortium is composed of one company focused in nanodelivery of antigen and mRNA using LNP, four groups of fish immunovirologists / vaccinologists and Quantoom for the DNA production aspect.